Dematteis: Since early December, Athersys , Inc. ( ATHX ) is up more than 100%, with ..... upside revaluation and, as such, Athersys is overvalued at its current price ..... A Quick Look at the Company Athersys is a development stage biotechnology
of life. In particular, two companies with a strong presence and even larger upside in treating such diseases are Athersys ( ATHX ) and NeoStem ( NBS ), and both might very well have a bright future. Cardiovascular Disease: A Very Important
By JDT Investments : Athersys ( ATHX ) is a clinical stage biotech company ..... article I took a comprehensive look at Athersys and provided more of a "big picture ..... article, or is not familiar with Athersys , I suggest doing so; the article
settling over $2 recently with most of those gains due to statistically significant Phase Ib clinical trial results . Athersys ( ATHX ) has risen from a 2013 closing price of $2.50 to over $4 before pulling back slightly with greatly increased
investors may want to take a look at Athersys , Inc. ( ATHX ) a quiet leader in the regenerative ..... financial leverage not available to Athersys in terms of ability to raise capital ..... look at the comparison between Athersys and Mesoblast later. Despite
By Red Bull : Only a few weeks in and 2014 is off to an interesting start! We weren't planning on another Neuralstem ( CUR ) related article so soon but media headlines have been flying fast and furiously within the regenerative medicine sector. Just two weeks ago, we covered what we like about ...
By U.S. Biotech Investor : Anxiously awaiting the second quarter data Athersys , Inc. ( ATHX ) and Pfizer, Inc. ( PFE ), after starting out with carefully chosen steps, are nearing completion of a phase II trial for
We are no longer providing equity research on Athersys ATHX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.